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Both acute myeloid leukemia and chronic myeloid leukemia are thought to arise from 
a subpopulation of primitive cells, termed leukemic stem cells that share properties 
with somatic stem cells. Leukemic stem cells are capable of continued self-renewal, 
and are resistant to conventional chemotherapy and are considered to be responsible 
for disease relapse. In recent years, improved understanding of the underlying 
mechanisms of myeloid leukemia biology has led to the development of novel and 
targeted therapies. This review focuses on clinically relevant patent applications and 
their relevance within the known literature in two areas of prevailing therapeutic 
interest, namely monoclonal antibody therapy and small molecule inhibitors in 
disease-relevant signaling pathways.
Myeloid leukemias are characterized by the 
accumulation of immature myeloid progeni-
tors caused by aberrations in cellular func-
tion, where deregulation of differentiation, 
growth and apoptosis leads to progression of 
an oncogenic phenotype [1–3]. The two com-
monest types of myeloid leukemia represent 
distinct disease entities – acute myeloid 
leukemia (AML) and chronic myeloid 
leukemia (CML). Improved understanding 
of the underlying mechanisms in their leu-
kemic biology has led to the development of 
novel and targeted therapies.
CML represents a prime example of the role 
that targeted therapies can play in improved 
disease outcome. CML is a clonal myelopro-
liferative disorder associated with a reciprocal 
translocation between the long arms of chro-
mosomes 22 and 9 giving rise to the Phila-
delphia chromosome and the subsequent 
formation of the BCR-ABL fusion gene, 
encoding the constitutively active tyrosine 
kinase BCR-ABL [4–7]. Advances in targeted 
therapies in chronic phase CML, notably the 
use of tyrosine kinase inhibitors (TKIs), have 
led to a tenfold reduction in disease progres-
sion to an accelerated or blast phase [8]. How-
ever, if left untreated, or in patients where 
resistance to TKIs exists or develops, the dis-
ease eventually progresses to blast phase, with 
terminal outcome in most cases [9,10].
Imatinib (Glivec, Novartis), the first BCR-
ABL-specific TKI to be used clinically, or the 
second generation TKIs, nilotinib (Tasigna, 
Novartis, Switzerland) and dasatinib (Spry-
cel, Bristol-Myers Squibb, USA), are used 
as first-line therapy for the management of 
patients with all phases of CML [11]. Sec-
ond-generation TKIs demonstrate increased 
pharmacological potency compared with 
imatinib. Nilotinib, like imatinib, binds an 
inactive conformation of BCR-ABL1, with 
30- to 50-fold increased binding affinity; 
whereas, dasatinib binds both active and 
inactive conformations of BCR-ABL1 and is 
325-times more potent [12]. The aim of treat-
ment is to achieve hematological, cytogenetic 
and molecular response at critical time points 
from treatment initiation (Table 1) [11]. This 
provides important prognostic information 
for disease progression [9,11,13].
With standard dose imatinib (400 mg 
daily), complete cytogenetic response 
(CCyR) is achieved in 49–77% of patients, 
with a major molecular response (MMR) 
in 18–58%, depending on the data stud-
ied [11,14–15]. However, despite this, 18% of 
patients do not achieve optimal response 
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(defined as quantitative BCR-ABL1 ≤0.1% at 12 
months and maintained thereafter [11]), 10% lose opti-
mal response and 4–8% are unable to tolerate ther-
apy [16,17]. Furthermore, 12–15% of patients will pres-
ent in the advanced stages of disease and are resistant 
to therapy. Resistance to therapy can occur through 
BCR-ABL-dependent mechanisms that rely on abnor-
malities within the structure of the target oncoprotein, 
including point mutations, such as T315I mutations; 
the third-generation TKI ponatinib, has been shown 
to be active against this mutation [18]. Further to this, 
recent in vitro studies provide strong evidence that 
CML leukemic stem cells (LSCs) are responsible for 
disease persistence despite a BCR-ABL-targeted thera-
peutic approach, and suggest BCR-ABL-independent 
mechanisms are being exploited to sustain their sur-
vival and proliferation [2,19]. TKIs are unable to target 
the resistant population of quiescent LSCs [20,21] mean-
ing that on cessation of TKI treatment the disease is 
likely to return [18,22–23].
AML, like CML, is a clonal disorder that arises fol-
lowing the gain of self-renewal potential of progeni-
tor cells, giving rise to a LSC. It is the most common 
malignant myeloid disorder in adults, with an annual 
incidence of approximately 3.8 per 100,000. Untreated 
AML typically results in bone marrow failure, leading 
to fatal infection, bleeding or organ infiltration, within 
1 year of diagnosis, but often within weeks to months. 
AML is categorized according to the WHO classifi-
cation which is based on cytogenetic and molecular 
abnormalities in the leukemic clone with known prog-
nostic significance (Table 2) [24]. Treatment and prog-
nosis vary significantly between the subtypes; with 
Table 1. European Leukemia Net criteria detailing minimum required response to first-line tyrosine kinase inhibitor 
therapy from initiation, with definitions of response†. 
Response Criteria
Complete heamatologic response (CHR) Normalization of peripheral blood 
and resolution of splenomegaly
Minimal cytogenetic response >65–95% Ph+ in bone marrow
Minor cytogenetic response >35–66% Ph+ in bone marrow
Partial cytogenetic response 0–35% Ph+ in bone marrow
Complete cytogenetic response (CCyR) 0% Ph+ in bone marrow
Major molecular response (MMR) 3 log reduction in BCR-ABL1 
relative to control
Complete molecular response (CMR) Undetectable BCR-ABL1 transcripts 
by qRT-PCR
Optimal Warning Failure
3 months BCR-ABL1 ≤10%  
±Ph+ <35% 
BCR-ABL1 >10% ±Ph+ 36–95% No CHR, and/or Ph+ >95%
6 months BCR-ABL1 <1%  
±Ph+ 0
BCR-ABL1 >10% ±Ph+ 1–35% BCR-ABL1 >10% and/or 
Ph+ >35%
12 months BCR-ABL1 ≤0.1% BCR-ABL1 >0.1–1% BCR-ABL1 >1% and/or 
Ph+ >0
Thereafter BCR-ABL1 ≤0.1% Confirmed clonal 
abnormalities, Ph
Loss of CHR; loss of CCyR; 
confirmed loss of MMR
†Data taken from [11]. 
BCR-ABL1: Quantitative PCR assessment of BCR-ABL1:ABL1 (or other housekeeping gene) on the International Scale; CCyR: Complete cytogenetic response; 
CHR: Complete hematologic response; CMR: Complete molecular response; MMR: Major molecular response; Ph+: Philadelphia chromosome positive. 
Key terms
Acute myeloid leukemia: Acute myeloid leukemia is 
a myeloproliferative neoplasm characterized by a rapid 
accumulation of abnormal white cells.
Chronic myeloid leukemia: Chronic myeloid leukemia 
is a myeloproliferative neoplasm that originates from an 
oncogenically active tyrosine kinase, BCR-ABL, generated 
by the Philadelphia translocation.
Philadelphia translocation: This is a chromosomal 
abnormality that is the result of a reciprocal translocation 
between chromosome 9 and chromosome 22.
Tyrosine kinase: A tyrosine kinase is an enzyme that can 
transfer a phosphate group from ATP to the amino acid 
tyrosine in a protein in a cell, thereby functioning to alter 
cellular function.
T315I mutation: The T315I mutation is caused by a 
single cytosine to thymine base pair substitution at codon 
315 of the Abl protein resulting in a threonine-isoleucine 
substitution
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overall survival varying from 20 to 47%, depending 
on subtype, mutational status and age.
Treatment, in itself, is associated with considerable 
morbidity and mortality. Standard chemotherapy for 
AML includes cytosine arabinoside (Ara-c) in conjunc-
tion with an anthracycline, such as daunorubicin or 
the nucleoside analogue fludarabine. While chemo-
therapy effectively induces remission in the major-
ity of patients with AML, the risk of relapse is high. 
The reasons for this are not completely understood, 
but conventional chemotherapeutics target proliferat-
ing cells and not the small number of quiescent LSCs 
postulated to initiate and maintain the disease [1,25–
26]. Therefore, disease relapse is likely to be a conse-
quence of failure to eradicate the residual LSC frac-
tion with conventional chemotherapies. Advances in 
the understanding of different molecular mechanisms 
involved in the pathogenesis of AML, including muta-
tional events, cell cycle aberrations and methylation 
status has led to the development of novel therapies. 
These have been reviewed extensively [26] and include 
the cell cycle inhibitors barasertib, volasertib and 
rigosertib and Flt3 receptor tyrosine kinases targeting 
mutational status, such as the inhibitors qiozartinib, 
sorafenib, midostaurin and creolanib [26]. Changes in 
DNA methylation have been shown to be integral in 
the development of leukemogenesis through tumor 
suppressor gene silencing. In AML, hypermethylation 
has been shown to be a poor prognostic marker exert-
ing a negative effect on chemotherapy induction out-
come, via p53-independent apoptosis. Hypomethylat-
ing agents are already in clinical use in the treatment 
of AML, and are beyond the scope of this review [27]. 
In patients with acute promyelocytic leukemia, a non-
chemotherapy approach is increasingly being adopted 
with the use of all trans-retinoic acid in combination 
with arsenic trioxide [28].
The identification of novel therapies that target the 
LSC population is a growing area of research and is of 
vital importance for developing treatment strategies 
which maintain remission and lead to possible long-
term cure of AML and CML. Targeted therapies for 
cancer aim to exploit molecular differences between 
normal and malignant cells to allow the specific removal 
of cancerous cells while sparing healthy cells. Many 
studies have examined the differences in gene expres-
sion between normal hematopoietic stem cells (HSC) 
and their leukemic counterparts to identify potential 
targets for therapy. This review focuses on clinically 
relevant patent applications of novel targeted therapies 
in myeloid leukemias, with particular attention focused 
on monoclonal antibody therapy and small molecule 
inhibitors of signal transduction within leukemia cells.
Antibody-mediated therapy
As a targeted form of cancer therapy, monoclonal 
antibodies have proven an attractive focus for recent 
research and have provided promising results for cer-
tain malignancies, usually in combination with con-
ventional chemotherapeutics [29]. Antibodies as cancer-
targeting therapies have been investigated since the 
early 1980s and immunotherapy with monoclonal 
antibodies has been used successfully in the clinic for 
the treatment of a number of cancers. Trastuzumab is 
used in cases of HER2-positive breast carcinomas [30]. 
Cetuximab targets EGFR in metastatic colorectal 
cancer [31], metastatic non-small-cell lung cancer [32] 
and head and neck squamous cell carcinomas [33]. 
Table 2. Prognostic risk in acute myeloid leukemia according to cytogenetic and molecular 
characteristics.
Prognostic risks Cytogenetic abnormalities Molecular abnormalities
Favorable Inv(16) or t(16;16) Normal cytogenetics;
 t(8;21) with isolated NPM1 or CEBPA mutation in 
the absence of FLT3-ITD
 t(15;17)  
Intermediate Normal cytogenetics t(8;21), inv(16), t(16;16): with c-KIT 
mutation
 Exon 8 trisomy  
 t(9;11)  
Unfavorable Complex karyotype Normal cytogenetics: with FLT3-ITD
 -5,5q-,-7,7q-11q23 inv(3), t(3;3)
 t(6;9)  
 t(9,22)  
Data taken from [24]. 
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Rituximab [34] and ofatumumab [35] target malignan-
cies with characteristic expression of CD20 on B-cells 
such as B-cell non-Hodgkin lymphoma and chronic 
lymphocytic leukemia (CLL) and alemtuzumab is 
used in the treatment of CLL and cutaneous T-cell 
lymphoma, where it targets CD52 on the surface of 
lymphocytes [36].
Therapeutic monoclonal antibodies work by a 
number of different mechanisms to target tumor cells 
(Figure 1). Antibody-dependent cellular cytotoxicity 
(ADCC) occurs when effector cells of the immune 
system lyse target cells ‘containing’ a specific antibody 
following antibody binding to Fc receptors (FcR) on 
the surface of the effector cell. ADCC is classically 
mediated by activation of NK cells through bind-
ing of the FcR CD16a (FcγRIIIA), but neutrophils 
(through CD64 (FcγRI), CD32 (FcγRII) and CD16 
(FcγRIIIB)), macrophages and eosinophils also par-
ticipate in ADCC. Once binding of the FcR occurs, 
the natural killer (NK) cell releases cytokines, such as 
IFN-γ, that can signal to other immune mediators, and 
release cytotoxic factors such as perforin and granzyme 
to initiate apoptosis in the target cell.
Complement-dependent cytotoxicity (CDC) is 
not the dominant antibody mediated mechanism of 
tumor cell kill, but does play a significant role and 
can enhance ADCC. Activation of the complement 
cascade is most effectively carried out by IgM type 
antibodies, but these are rarely used in the clinical 
setting due to their difficulty in crossing the vascular 
wall [37]. However, IgG1 and IgG3 are able to activate 
complement via CDC. When antibody binds to anti-
gen, C1q-binding sites are uncovered allowing higher 
avidity binding to IgG, triggering the complement 
cascade and proteolytic release of effector cell activat-
ing agents C3a and C5a. The membrane attack com-
plex (MAC) containing C5b, C6, C7, C8 and C9, is 
then formed which causes osmotic lysis of target cells. 
Rituximab [38], alemtuzumab [39] and ofatumumab [40] 
have been shown to depend in part on CDC for their 
in vivo efficacy.
In addition to their effects on cellular cytotoxicity, 
the majority of clinically effective monoclonal anti-
bodies work by perturbing signaling pathways essen-
tial for the promotion of proliferation and survival of 
tumor cells. For example, overexpression of growth 
factor receptors is common on tumor cells and can be 
targeted by antagonistic antibodies that modulate their 
ability to influence mitogenic signaling pathways [41]. 
Cetuximab functions as a competitive antagonist of 
EGFR to inhibit ligand binding, resulting in inhibi-
tion of downstream signaling and cell proliferation [42]. 
IgG2 and IgG4 type antibodies are unable to activate 
either ADCC or CDC and work only by modulating 
signaling pathways, resulting in fewer immune related 
adverse events (irAE) [43,44].
Perhaps the most important factor associated with 
antibody-mediated therapy success is the induc-
tion of adaptive immunity. Following ADCC or CDC, 
fragments of tumor cells are released and taken up by 
antigen-presenting cells (APCs) such as dendritic cells 
(DCs) where they are presented on the surface by the 
major histocompatibility complex class II (MHCII) to 
prime CD4+ T-cells or by MHC I to generate tumor 
specific CD8+ T-cells [44,45]. These cytotoxic T-cells 
can then target and kill cells containing the tumor 
antigen or differentiate into tumor-specific memory 
T-cells [46]. Clinical data are emerging to suggest 
that the induction of adaptive immunity will likely 
play a substantial role in whether antibody-mediated 
therapies are successful [47,48].
As described, in AML the residual LSC fraction of 
cells following conventional chemotherapies can lead 
to disease relapse. CD123 [49], CD25 [50], CD32 [50], 
CD47 [51], CD44 [52], CD96 [53], CLL-1 [54] and 
CD33 [55] have all been demonstrated to be differen-
tially expressed on AML LSC compared with normal 
HSC (Table 3). Of these, the most attractive antibodies 
currently being investigated for the treatment of AML 
are anti-CD33 and anti-CD123.
CD33 (Siglec-3) is a myeloid lineage-specific anti-
gen expressed on early myeloid progenitors, most 
monocytic cells and approximately 90% of AML 
blasts, but absent on normal HSCs [66]. The human-
ized monoclonal anti-CD33 antibody lintuzumab 
appeared promising in early clinical trials [67], but 
was abandoned during Phase IIb trials after patient 
survival rates did not increase significantly [68]. Fol-
lowing this, the calicheamicin-conjugated anti-CD33 
monoclonal antibody gemtuzumab ozogamicin (GO; 
Myelotarg, Pfizer, USA) was granted accelerated 
approval by the US FDA following good response rates 
in Phase II trials [69,70]. However, GO was voluntarily 
removed from the market in 2008 following increased 
incidence of death [71] and limited clinical benefits over 
conventional cancer therapies in Phase III clinical tri-
als [71–73]. It is likely that the adverse effects of GO 
were due to dissociation of calicheamicin from the 
anti-CD33 antibody causing increased toxicity [74]. 
Further Phase III studies have demonstrated improved 
remission rates and survival in both younger and older 
patients receiving GO in combination with conven-
Key term
Antibody-mediated therapy: Form of immunotherapy 
that typically uses a monoclonal antibody to specifically 
bind to a target cell, leading to the subsequent immune 
destruction of that cell.
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tional chemotherapy as AML remission induction 
therapy [75,76]. Anti-CD33 therapy therefore remains 
a viable and potentially attractive option for the treat-
ment of AML. A recent patent [56] has examined mak-
ing these antibodies of higher affinity to the CD33 
receptor enabling their use as recombinant fragments 
for immunotargeting. By varying the sequences of 
the antibody complementary determining regions 
(CDRs), it is proposed that more effective, higher 
affinity binding can be achieved with these modified 
CD33 antibodies. These antibodies remain bound to 
the cell surface for longer, improving binding affinity 
and can be further modified by addition of effector 
groups such as pharmaceutically active substances and 
radioactive isotopes allowing tumor cells to be effec-
tively targeted. In addition, antibodies can be conju-
gated to a further antibody to allow what is known as 
bispecificity or to two additional antibodies to allow 
trispecificity [77–79]. These are typically antibodies 
specific to effector cells such as NK cells, cytotoxic 
T-cells, monocytes, macrophages or DCs allowing 
more effective targeting for CDC or ADCC. In a 
recent patent, [57], a trispecific antibody for targeted 
AML therapy that included binding to CD33, CD123 
and CD16 was described. Bispecific antibodies bind-
ing CD19 and CD16, with cytolytic activity directed 
Figure 1. Mechanisms of action of monoclonal antibody-mediated therapy. Complement dependent cytotoxicity 
is an immune process that occurs following binding of an antibody to an antigen, where the complement 
cascade is activated. This leads to the formation of the terminal membrane attack complex in the cell membrane 
leading to lysis and death. Antibody-dependent cellular cytotoxicity occurs when the Fc receptor of effector cells 
(NK cells, macrophages) binds to the Fc portion of an antibody that has bound to a target cell. Following binding 
the effector cell can release cytokines for example that cause lysis of the target cell. Therapeutic monoclonal 
antibodies can also directly target cells by being conjugated to radionuclides, toxins, drugs and other substances 
that cause cells to die. 
ADCC: Antibody-dependent cellular cytotoxicity; CDC: Complement-dependent cytotoxicity.
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against leukemic cells have been described [80,81]. A 
bispecific antibody (blinatumomab) to CD19 and 
CD3 has been evaluated in Phase I and II clinical trials 
with promising results in CD19-expressing lymphoid 
malignancies [82]. In the case of the invention in pat-
ent [57], the molecule consists of three scFvs covalently 
linked in tandem (single-chain Fv triplebody [sctb]), 
two that have specificity to the tumor cell (CD33 and 
CD123) and one to an effector cell (NK, monocytes 
or macrophage; CD16). The therapeutic effect of this 
trispecific antibody is direct elimination of the can-
cer cell by ADCC in addition to generating apoptotic 
fragments from the tumor cell that are taken up and 
presented by CD4+ and CD8+ T-cells [83].
CD123 (IL-3Rα) is expressed on AML LSCs [49,84–
87]. Initially described in the patent [58], CD123 
monoclonal antibodies have been identified as poten-
tial therapies in the treatment of AML. Monoclonal 
antibodies to CD123 (CSL362) have proved effective 
in vitro and in animal models in enhancing ADCC 
through NK cells [88]; however, recent Phase I clinical 
trials of the anti-CD123 (CSL360) antibody for treat-
ment of relapsed, refractory or high-risk AML showed 
that while it was safe, there was limited efficacy [89].
Other siglecs (in addition to CD33/siglec-3) such as 
the recently described siglec-15 have also been identi-
fied as potential targets for antibody-mediated ther-
apy [59]. The advantage of targeting siglec-15 in AML 
instead of CD33 is that theoretically the majority of 
the toxic side-effects associated with targeting CD33 
such as myelosuppression and/or hepatotoxicity would 
be avoided. This is because there are much lower levels 
of siglec-15 on peripheral blood leukocytes and high 
levels on AML blasts, so nonspecific cell kill would 
be reduced. Other potential targets in AML such as 
CD44 [60], TIM-3 [61] and GM-CSF receptor α [62] 
have been the subject of recent patent applications. 
Anti-CD44 (H90/P245) showed some promise as an 
agent for targeting LSCs, with preclinical studies dem-
onstrating eradication of LSCs and cure of leukemic 
NOD/SCID mice [52]. These antibodies would likely 
have limited effect in vivo as they were of murine ori-
gin, but chimeric antibodies (γ 1 construct and γ 4 
construct) as described in the application [60] would in 
Table 3. Antibody-mediated therapies patent applications.
Target Patent number In vitro data 
in myeloid 
leukemia
In vivo data 
in myeloid 
leukemia
Clinical Trial 
data in myeloid 
leukemia
Ref.
CD33 US20120251554 Anti-CD33 antibodies and use thereof 
for immunotargeting in treating CD33-
associated illnesses
+ - - [56]
CD123 US20120328619 Tri-specific therapeutics against acute 
myeloid leukemia
+ - - [57]
CD16       
CD33       
CD123 EP2329847 Use of an antibody or an immunotoxin 
that selectively binds to CD123 to impair 
hematologic cancer progenitor cells
+ - - [58]
Siglec-15 CA2848074 Anti-Siglec-15 antibodies and uses thereof + - - [59]
CD44 EP2275444 Chimeric anti-CD44 antibodies and their 
use for treating acute myeloid leukemia
+ - - [60]
TIM-3 US20140134639 Method for treatment of blood tumor 
using anti-TIM-3 antibody
+ - - [61]
GM-CSF 
receptor α
US20140079708 Antibody molecule for human GM-CSF 
receptor α
+ - - [62]
CLL-1 US20140248633 Leukemia stem cell targeting ligands and 
methods of use
+ - - [63]
ITM2A US20140193420 Diagnosis and treatment of cancer using 
anti-ITM2A antibody
+ - - [64]
CXCR4 WO2013071068 Treatment of hematologic malignancies 
with an anti-CXCR4 antibody
+ + - [65]
+: Evidence available; -: No evidence available.
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theory remove some of the issues associated with the 
murine antibody, while retaining the ability to induce 
ADCC or CDC (γ 1). C-type lectin-like molecule-1 
(CLL-1) is another good potential target for the eradi-
cation of AML stem cells [90]. The patent [63] describes 
the binding of specific peptides/polypeptides to the 
surface of AML LSC expressing CLL-1 and the subse-
quent delivery of toxic or drug payloads to the cell to 
allow an effective cell kill. The patent [91] describes the 
use of human monoclonal anti-CXCR4 antibodies to 
target AML cells by disrupting the interaction between 
CXCR4 and its ligand CXCL12. The CXCR4 antago-
nists AMD3100 and AMD3465 have previously been 
shown to increase chemosensitization of AML cells by 
blocking signaling through this pathway [92,93] and 
lower levels of CXCR4 on AML cells correlate with 
better prognosis and survival [94]. The anti-CXCR4 
antibody described binds with low nanomolar affin-
ity and is shown to decrease tumor proliferation and 
increase induction of apoptosis. The invention in pat-
ent [64] describes a monoclonal antibody against the 
type II membrane protein ITM2A for the potential 
treatment of AML by inducing ADCC.
Currently the most topical potential therapeutic 
monoclonal antibody in AML is CD47 (Table 4). CD47 
binds the ligands thrombospondin-1 (TSP-1) and sig-
nal regulatory protein α (SIRP-α) and is involved in 
apoptosis, proliferation, adhesion and migration [95]. 
Increased expression of CD47 has been shown to be a 
poor prognostic factor in AML [51].
One of the major modes of clearance of apoptotic leu-
kemic cells is by macrophage-mediated phagocytosis. 
To avoid immune surveillance by macrophages, AML 
cells upregulate CD47 [101]. The patents [96] and [97] 
describe methods to enhance phagocytosis of circu-
lating CD47-expressing LSC by blocking cell surface 
CD47. Blocking CD47 with a monoclonal antibody 
prevents the interaction between CD47 and SIRP-α 
leading to increases in phagocytic clearance of LSCs. 
Additionally, the patents describe aspects of antibody 
bispecificity, where CD47 is used synergistically with 
other monoclonal antibodies directed against other 
cell surface markers unregulated in AML stem cells 
to enhance phagocytic clearance [96]. Additionally, by 
combining a monoclonal antibody specific to CD47 
with a cytotoxic agent such as a chemotherapeutic 
agent, radio-isotope or toxin, LSCs expressing CD47 
can be targeted directly on antibody binding. Refer-
ence [65] also describes therapeutic antibodies targeting 
CD47 that disrupt the interaction with SIRP-α lead-
ing to increased phagocytic uptake. Other methods 
targeting the interaction between CD47 and SIRP-α 
are described in [98]. By using polypeptides capable of 
binding specific sequences within CD47 or SIRP-α, 
the interaction between each can be modulated to 
enable macrophage activation, leading to clearance of 
leukemic cells. Patents describing humanized mono-
clonal antibodies that bind and neutralise CD47 and 
that have low immunogenicity in humans have been 
filed [99,100]. The benefits of using humanized antibod-
Table 4. CD47 antibody-related patent applications.
Patent number In vitro data in 
myeloid leukemia
In vivo data 
in myeloid 
leukemia
Clinical trial 
data in myeloid 
leukemia
Ref.
WO2014093678 Therapeutic CD47 
antibodies
- + - [91]
US20140161805 Methods for manipulating 
phagocytosis mediated by 
CD47
+ + - [96]
US20140161825 Methods of treating acute 
myeloid leukemia by 
blocking CD47
+ + - [97]
US20120189625 Compositions and methods 
for treating hematological 
cancers targeting the 
SIRP-α CD47 interaction
+ + - [98]
US20120156724 Humanized anti-CD47 
antibody
- - - [99]
US20130142786 Humanized and chimeric 
monoclonal antibodies to 
CD47
+ - - [100]
+: Evidence available; -: No evidence available.
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ies in immunotherapy are a significant reduction in 
host immune responses following administration.
There is limited evidence of the use of monoclo-
nal antibody therapy in CML. There has been a lim-
ited number of reports indicating the use of GO in 
myeloid blast phase and rituximab in lymphoid blast 
phase CML, both in combination with conventional 
chemotherapy with some success, but there are no pat-
ents specific to these indications [102,103]. Additionally, 
one report identified CML stem cells based on their 
expression of the IL-1 receptor accessory protein (IL-
1RAP) [104]. The authors demonstrated a reduction in 
CML stem cells by ADCC when a rabbit polyclonal 
antibody was administered to CML cell lines and to 
primary CD34+CD38- cells. However, with the success 
of TKIs in CML, it is unlikely that antibody-mediated 
therapies will represent a major new therapeutic class 
in CML in the immediate future.
Small molecule inhibitors of signal 
transduction
Signal transduction is the primary method used by 
eukaryotic cells to respond to external cues within their 
microenvironment [105], and is fundamental to normal 
cellular processes. Deregulation within these signals is, 
unsurprisingly, critical in the pathogenesis of leukemia. 
Studies have shown that abnormal signal transduction 
enhances the self-renewal, proliferative and anti-apop-
totic capacity in AML and CML LSC [106–111], and tar-
geting these pathways offers an attractive alternative to 
conventional chemotherapy [112].
Large numbers of aberrant signaling proteins have been 
identified in both AML and CML – these reflect a more 
limited number of signaling pathways, such as mamma-
lian target of rapamycin complex 1/phosphatidylinosit-
ide 3-kinases/AKT (mTORC1/PI3K/Akt) [113,114], 
Wingless-Int/β-Catenin (Wnt/β catenin) [115,116], 
Hedgehog (Hh) [117–119] and Notch [108–109,120]. These 
pathways are known regulators of cell survival, namely 
self-renewal and apoptosis, and are often differentially 
expressed following genetic events [111,114,121]. When 
deregulated, these signaling pathways have been impli-
cated in neoplastic pathogenesis [107,109,113,116,119,122]. Tar-
geting these unifying pathways may represent a more 
broadly applicable therapeutic strategy compared with 
conventional chemotherapy alone in myeloid leukemias. 
However, these pathways do not act in isolation, relying 
on intricately interwoven networks, leading to the devel-
opment of myeloid leukemia, its progression [107] and 
LSC survival [123]. CML serves as a paradigm example 
into the complexities and orchestral approach between 
the pathways in leukemia pathogenesis.
In CML, the fundamental role of BCR-ABL is well 
documented [124,125]. The oncogenically active tyrosine 
kinase, BCR-ABL, activates many signal transduction 
pathways essential for cell survival and proliferation. 
Activation of downstream pathways occurs, in part, 
from the autophosphorylation of the BCR-ABL1 domain 
with the subsequent suppression of forkhead O (FOXO) 
transcription [126], through activation of the PI3K/Akt 
pathway [127], and activation of RAS, promoting leuke-
mic cell survival through MAPK. Furthermore, it has 
been demonstrated that BCR-ABL1 can lead to the 
direct phosphorylation and activation of STAT5 [128]. 
Thus, there are many potential small molecule inhibi-
tors with targets downstream of BCR-ABL that have 
been assessed for their potential as LSC-eliminating 
agents. Furthermore, as self-renewal activation is char-
acteristic of LSCs, further therapeutic targets could lie 
in the evolutionary conserved self-renewal pathways, 
Wnt, Hh and Notch [115,119–120]. Additional signaling 
abnormalities characterise CML progression to the 
more acute blast phase of disease, including the Numb-
Musashi signaling network; although, whether this 
exerts its effects through the self-renewal pathways, Hh 
or Notch, has yet to be established [129].
The complexities in interaction between these 
pathways are well documented. In CML, the Hh 
pathway has been linked to LSC generation, disease 
progression and the modulation of the hematopoietic 
microenvironment [130]. Wnt has been shown to play 
a critical role in the survival of LSCs with acquired 
imatinib resistance [131], and it has been demonstrated 
that a recurrent misspliced, non-functional isoform of 
GSK3β predominates in the granulocyte-macrophage 
progenitor population in myeloid blast phase, leading 
to enhanced self-renewal via the Wnt pathway [131,132]. 
In addition, interactions between the Hh and Wnt 
pathways have been shown to be deregulated in CML 
development and progression [106,115–116,133].
As with CML, the aberrations seen in AML can be 
related to similar signaling pathways [134]. However, the 
genetic variations seen in AML render the intricacy of 
signal transduction interaction more complicated. For 
example, Flt3 mutations (detected in approximately 
30% of AML [135]) mediate their proliferative and 
anti-apoptotic oncogenic effects through varying sig-
naling pathways, including STAT5, RAS/MAPK and 
PI3K/Akt. Therefore, activating mutations can lead 
to deregulation in more than one signaling pathway. 
The pathways can also be activated simultaneously, as 
demonstrated in patients with RAS mutations, where 
both RAS/MAPK and PI3k/Akt pathways can be acti-
vated simultaneously [136]. The diversity of molecular 
abnormalities in AML makes developing a therapeu-
tic regimen that is efficacious in all activated pathways 
unachievable and, increasingly, we are moving to an 
individualized treatment approach in AML based on 
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molecular and cytogenetic abnormalities, prognostic 
risk group and age. In view of the complexities seen 
within the interactions of signal transduction path-
ways, each clinically relevant pathway and its associated 
patent applications will be discussed individually.
mTOR/PI3K/Akt signaling pathway
The PI3K/Akt signaling pathway plays a significant 
role in a number of cellular functions, including differ-
entiation, apoptosis and cell cycle progression [137,138]. 
Aberrant signaling of the pathway has been linked to 
a number of oncogenic disease processes [139], includ-
ing AML and CML [111,137], where it has been shown 
to influence survival and drug resistance of immature 
progenitors and LSCs [137]. The mTOR signaling path-
way is critical to normal hematopoiesis and has been 
shown to be frequently mutated in hematological 
malignancies and TKI-resistant myeloid disease [137–
138,140–141]. mTOR is a serine/threonine kinase with its 
activity within a cell being conducted by two distinct 
complexes (mTORC1 and mTORC2), with mTORC1 
being strongly associated with neoplastic prolifera-
tion. One of its main substrates, p70-S6k, is known 
to inhibit autophagy – an area of increasing interest in 
myeloid disease, particularly in CML [141,142]. Although 
patent applications have been generated for small mol-
ecule inhibitors toward autophagy in malignancy, their 
direct role in myeloid disease is not listed.
The interactions between mTOR and PI3K/Akt are 
complex, with negative feedback loops at its core; this 
has been previously reviewed in detail [138]. Briefly, the 
binding of a growth factor ligand (e.g., insulin, TGF-β 
or VEGF) to the receptor tyrosine kinase results in 
receptor activation, which in turn, activates PI3K, 
through phosphoinositide-dependent kinase 1 (PDK1). 
PI3K activity subsequently results in Akt activation 
that directly phosphorylates and activates mTOR, as 
well as inhibits the mTOR inhibitor proteins, pro-
line-rich Akt/PKB substrate 40 kDa (PRAS40) and 
tuberin. Combined, these actions promote cell growth, 
cell proliferation and inhibit autophagy through 
downstream targets (Figure 2). The pathways are fre-
quently activated in both AML and CML, with aber-
rant PI3K/Akt activation being reported in 50–80% 
of AML cases [137]; simultaneous activation with other 
pathways conferring a poor prognosis. The PI3K/Akt 
Figure 2. Regulation of cellular function through the PI3K/Akt-FOXO signaling network. The binding of a ligand 
(including insulin, TGF-β and VEGF) to the receptor tyrosine kinase results in receptor activation, which in turn, 
activates PI3K through PDK1. PI3K activity subsequently results in Akt activation that directly phosphorylates and 
activates mTORC1. BCR-ABL activates Akt. Akt negatively regulates the FOXO proteins and prevents translocation 
to the nucleus, and the FOXO proteins normal function, therefore leading to activation of cell cycle genes, 
including MYC and CYCLIN D2. Combined, these actions promote cell growth, cell proliferation and inhibit 
autophagy through downstream targets.
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pathway is a key downstream target of BCR-ABL, with 
mTORC1 inhibition acting synergistically with TKIs 
to induce apoptosis [141,143]. Recent patent applica-
tions describe a selection of compounds available for 
the inhibition of mTOR/PI3K/Akt (Table 5), but their 
exact mechanism in myeloid disease or bioavailability 
for therapeutic use are not available via these patent 
applications. However, a recent publication describes 
their potential benefits in both in vitro and in vivo set-
tings [143]. Furthermore, the synergistic effect in vitro of 
Akt-1 inhibitors and Flt3 TKIs has been documented 
extensively in the published literature, but without rel-
evant associated patent applications [144]. Inhibition 
of PI3K or mTORC1 has previously demonstrated a 
growth disadvantage in AML. Inhibiting PI3K/Akt 
with LY294002, a potent PI3K inhibitor, can control 
blast cell proliferation [145]. First-generation mTORC1 
inhibitors offered potentially promising initial results 
in terms of apoptotic ability, but long-term apoptotic 
advantages were disappointing [146]. Although, there 
are no patent applications specifically detailing the role 
of PI3K or mTORC1 inhibition in myeloid leukemias, 
early phase clinical trials are ongoing to assess the role 
of PI3K or mTOR inhibitors in both AML and CML. 
A Phase Ib study analyzing the combined effect of the 
mTORC1 inhibitor, RAD001 and conventional che-
motherapy demonstrated the possibility of improved 
treatment outcome in AML [147]. The lack of specific 
patent application in this area, therefore, does not 
diminish the importance of this pathway as a clinically 
relevant therapeutic target in the future.
Dual inhibition of mTORC1 and mTORC2 may 
offer an interesting possibility for therapeutic advan-
tage as simultaneous inhibition of mTORC1 and 2 
Table 5. mTOR/PI3k/Akt signaling pathway-related patent applications.
Patent number In vitro data 
in myeloid 
leukemia
In vivo data 
in myeloid 
leukemia
Clinical trial 
data in myeloid 
leukemia
Ref.
WO2009008992 Combination anticancer therapy comprising 
an inhibitor of bone mTORC1 and mTORC2
- - - [148]
WO2012106702 Treatment of leukemia + + - [149]
US20130045188 Reduction of TGF-β signaling in myeloid cells 
in the treatment of cancer
+ + - [150]
US7928248 Benzoxepin PI3K inhibitor compounds and 
methods of use
- - - [151]
CA2680853 Delta3-substituted quinoline or 
quinoxaline derivatives and their use 
as phosphatidulinositol 3-kinase (PI3K) 
inhibitors
- - - [152]
WO2013141586 Novel pyridopyrimidine derivatives that 
inhibit PI3K
- - - [153]
WO2013104611 Sustituted pyrazolopyrimidines that are PI3K 
and Akt inhibitors
- - - [154]
WO2013104610 Substituted imidazopyrazines that are PI3K 
and Akt inhibitors
- - - [155]
WO2013049581 A PI3K inhibitor and a poly(ADP-Ribose) 
polymerase inhibitor; useful for treating 
cancer
- - - [156]
WO2013052699 Novel Quinoxaline inhibitors or PI3K; useful 
for treating cancer and inflammatory 
diseases
- - - [157]
WO2013095761 Imidazopyridine derivatives that are selective 
PI3KB inhibitors and can be used to treat 
cancer
- - - [158]
WO2013066483 Synergistic combinations of PI3K and 
MEK inhibitors that can be used to treat 
proliferative disease
- - - [159]
+: Evidence available; -: No evidence available.
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induces apoptosis in T315I mutated BCR-ABL positive 
cells, indicating its potential relevance as a therapeu-
tic target in TKI-resistant CML [127]. A patent appli-
cation [148] described this dual inhibitory approach in 
mesenchymal and epithelial non-small-cell lung cancer 
and ovarian cancer cell lines, but did not specifically 
detail a myeloid phenotype.
The Akt network controls many different down-
stream targets including the FOXO family of tran-
scription factors as described above (Figure 2) [160]. 
When unphosphorylated, the FOXOs localize in the 
nucleus, enabling transcription of a wide array of target 
genes involved in cell cycle and apoptosis. PI3K activa-
tion, downstream of growth factor receptors negatively 
regulates FOXO proteins. It is hypothesized that the 
FOXO transcription factors are activated via BCR-
ABL-Akt signaling [126,161] and this maintains CML 
LSC quiescence. No patent applications are currently 
available in respect of FOXO signaling in CML.
Paradoxically, the patent application [149] suggests 
that inhibition of FOXO, rather than activation, could 
be protective in AML; in both in vitro CD34+ pro-
genitor cells and in vivo in a MLL-AF9-induced AML 
mouse model. Moreover, TGF-β is a critical regulator 
of Akt activation in CML leukemia-initiating cells 
and also controls FOXO nuclear localization [161]. In 
a recent patent application, [148], Yang et al. provide 
evidence as to the importance of TGF-β in malig-
nancy and metastasis, particularly in lung disease, by 
manipulating TGF-β receptor II expression in myeloid 
cells in vitro, ex vivo and in vivo, using RNA interfer-
ence, and transgenic mouse models. Although not 
limited to myeloid disease, the invention suggests the 
importance of the TGF-β in the PI3K/Akt pathway in 
malignancies where TGF-β is upregulated.
Targeting self-renewal pathways
In view of the fact that committed progenitors gain 
self-renewal properties in AML and blast phase CML, a 
number of evolutionary conserved self-renewal pathways 
are generating increasing interest as novel therapeutic 
agents.
Hedgehog signaling pathway
The Hh signaling pathway is inappropriately activated 
in many human malignancies, including CML [162–165] 
and AML [117,118]. Recent evidence suggests that Hh 
signaling is critical for the maintenance and expan-
sion of cancer stem cells, and is a key candidate for 
LSC-directed therapy.
The patent application [166] presents the inven-
tion of a dual-therapy treatment approach in CML, 
comprising a first agent that inhibits the Hh signal-
ing pathway and a second that inhibits BCR-ABL. 
The experimental data assessed primary patient sam-
ples obtained from newly diagnosed and untreated 
patients with CML in chronic phase. These cells were 
enriched for CD34+ progenitor cells prior to analysis. 
In addition, mouse bone marrow cells were infected 
with a bicistronic retroviral Bcr-Abl vector, cultured 
for 82 h in the presence of the Hh, compound A, then 
plated to assess clonogenic colony formation. In all 
cases, the Hh inhibitor reduced the clonogenic capac-
ity of the BCR-ABL-expressing cells. These results 
were confirmed in vivo in the murine model. This 
suggests that a combinatorial approach may ben-
efit patients with primary, relapsed, transformed or 
refractory forms of CML.
In a patent application, [167], the Smoothened 
inhibitor, PF-04449913, demonstrated reduction in 
leukemia progenitor survival in both in vitro and in 
vivo models of CML LSC. In vivo, blast phase CML 
LSC engrafted mice treated with and without com-
bined PF-04449913 and dasatinib showed a signifi-
cant reduction in disease and BCR-ABL expression if 
the Hh inhibitor was used in combination with TKI. 
It was demonstrated that inhibition of this pathway 
could push the LSC from G0 to G1 of the cell cycle, 
which increased their susceptibility to BCR-ABL inhi-
bition. In a Phase Ia study presented at The American 
Society of Hematology (2013) it was demonstrated 
that PF-04449913 could synergize with BCR-ABL 
inhibition to reduce blast crisis LSC survival and self-
renewal, but with increased expression of Hh pathway 
regulators, suggesting that it is selective Hh antago-
nism that induces cell cycle interference of dormant 
human blast crisis LSCs [168].
Other modulators of the pathway (Table 6) have 
been described via patent application, but the relevance 
in myeloid leukemia has yet to be determined.
Notch signaling pathway
The Notch pathway has been implicated in a num-
ber of malignancies with its role being cell and tissue-
dependent. In cancer biology, Notch signaling has 
been demonstrated to play both an oncogenic and 
tumor suppressive role, depending on cell and cancer 
type [171–176]. In hematopoietic malignancies, accu-
mulating evidence demonstrates its importance in 
growth, differentiation and apoptosis [177,178]. Reports 
about the role that Notch plays in myeloid disease are 
conflicting, as Notch activation in myeloid precursors 
has been shown to promote self-renewal, induce and 
inhibit differentiation to monocytes or induce apop-
tosis [179–182]. A recent patent application, [183], dem-
onstrated that the Notch signaling pathway is silenced 
in human AML, as well as in AML-initiating cells in 
an in vivo model of the disease. Furthermore, in vivo 
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activation of Notch signaling using genetic Notch 
gain-of-function models or in vitro using synthetic 
Notch ligand induced rapid cell cycle arrest, differen-
tiation and apoptosis of AML-initiating cells. These 
data demonstrated a potential novel tumor suppressor 
role for Notch signaling in AML and elucidated the 
potential therapeutic use of Notch receptor agonists 
in its treatment. There is currently no patent applica-
tion focusing on the agonistic therapeutic implication 
of Notch signaling in CML.
Wnt/β-catenin
The Wnt signaling pathway plays an essential role 
the proliferation, survival and differentiation of 
LSCs [184]. Constitutive activation of Wnt signaling 
has been reported in both AML and CML [115,184]. 
Zhao et al. revealed that β-catenin deletion reduces 
the ability of mice to develop Bcr-Abl positive leuke-
mia, suggesting an integral role for β-catenin in the 
pathogenesis of CML [115]. Furthermore, increased 
activation of the pathway has been associated with 
poor response in blast phase CML [106]. The patent 
application, [185], discloses the use of an anthracene-
9,10-dione dioxime compound: 2-((3R,5S)-3,5-di-
methylpiperdin-1ylsulfonyl) -7- ((3S,5R)-3,5-di-
methylpiperidin-1-ylsulfonyl)anthracene-9,10-dione 
dioxime, in the disruption of tranducin β-like protein 
1 (TBL1)’s interaction with β-catenin in AML cells, 
as well as CML cell lines. Recent studies have shown 
that TBL1 is able to activate the Wnt/β-catenin path-
way by binding to both β-catenin and the Wnt pro-
moter complex. Further, TBL1 appears to protect 
β-catenin from ubiquitination and degradation [186]. 
However, the mechanism of the interaction between 
TBL1 and β-catenin remain unknown.
Conclusion & future perspective
This review describes the clinically relevant novel 
therapeutic targets in myeloid leukemia that have 
been the subject of recent patent applications. The 
main areas of focus were monoclonal antibody thera-
pies and clinically relevant small molecule inhibi-
tors of signal transduction; however, this list is not 
exhaustive.
The treatment of myeloid leukemias represents 
an exciting area of research where novel therapeutic 
advances are being discovered; but it is an area of 
research with great complexity. A limiting factor in 
discussing the patent applications is the lack of consis-
tency in describing cell line and primary cell in vitro 
models and in vivo murine models between the appli-
cations. Furthermore, the clinically important aspect 
of any novel therapeutic target is in its ability to be 
administered with manageable toxicity and still dem-
onstrate efficacy. This relies on its biological effect on 
other systems and is not often described within the 
patent applications.
The novel therapeutic targets described offer excit-
ing prospects for improving therapeutic outcomes 
in patients with myeloid leukemias with a potential 
reduction in treatment toxicity. Some of these novel 
therapeutic approaches may even target the elusive 
LSC. It remains to be seen if the inhibition of signal-
ing pathways and monoclonal antibody therapy will, 
indeed, prove to be clinically effective in AML and 
CML, and few novel therapies (with the exception of 
BCR-ABL-specific TKIs) have been licensed for use 
in myeloid leukemias in recent years. It is likely that 
the identification of novel targets and novel therapeu-
tic strategies in myeloid leukemias will remain a rich 
source of patent applications in the future.
Table 6. Hedgehog pathway-related patent applications.
Patent number In vitro data 
in myeloid 
leukemia
In vivo data 
in myeloid 
leukemia
Clinical trial 
data in myeloid 
leukemia
Ref.
CA2769300 Methods and compositions 
for treating leukemia
+ + - [166]
WO2013036867 Compositions and methods 
for cancer and cancer 
stem cell detection and 
elimination
+ + - [167]
WO2009074300 Benzimidazole derivatives 
as hedgeog pathway 
antagonists and therapeutic 
applications thereof
- - - [169]
WO2008112913 Inhibitors of the Hedgehog 
pathway
- - - [170]
+: Evidence available; -: No evidence available.
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Executive summary
Background
•	 Both acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are thought to arise from a 
subpopulation of primitive cells, termed leukemic stem cells (LSCs), that share properties with somatic stem 
cells.
•	 LSCs are capable of unlimited self-renewal, and are resistant to therapy, with conventional chemotherapy 
being unable to eradicate them.
•	 The identification of novel therapies that target the LSC population is a growing area of research of vital 
importance for maintaining remission and possible cure of AML and CML.
Antibody-mediated therapy
•	 Monoclonal antibodies have proven an attractive focus for recent research and have provided promising 
results for certain malignancies usually in combination with conventional chemotherapeutics.
•	 CD123, CD25, CD32, CD47, CD44, CD96, CLL-1 and CD33 have all been demonstrated to be differentially 
expressed on AML LSC compared with normal hematopoietic stem cells.
•	 Currently the most topical potential therapeutic monoclonal antibody in AML is CD47.
•	 Increased expression of CD47 has been shown to be a poor prognostic factor in AML.
•	 Examples of recent patent applications and the associated scientific literature is discussed within this section.
Small molecule inhibitors of signal transduction
•	 Studies have shown that abnormal signal transduction enhances the self-renewal, proliferative and anti-
apoptotic capacity in both AML and CML LSC.
•	 Targeting these pathways offers an attractive alternative to conventional chemotherapy.
•	 Many signaling pathways have been shown to be deregulated, including mTOR/PI3K/Akt, Notch, Hedgehog 
and Wnt.
•	 Interactions within the pathways make developing a therapeutic regimen that is efficacious in all activated 
pathways difficult.
•	 Examples of recent patent applications and the associated scientific literature is discussed within this section.
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